Navigation Links
Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Date:8/22/2008

inical data suggests that combining HGS-ETR1 with chemotherapy agents could be an effective approach to the treatment of a number of malignancies, including non-small cell lung cancer," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS. "HGS-ETR1 is the most advanced of any product in development that targets the TRAIL apoptotic pathway. The NSCLC study is one of three ongoing HGS trials designed to evaluate combinations of HGS-ETR1 with chemotherapeutic agents for the treatment of specific cancers."

About the HGS-ETR1 Proof-of-Concept Trials

The HGS-ETR1 proof-of-concept phase includes three randomized trials to evaluate its potential in combination with chemotherapy for the treatment of specific cancers:

-- Randomization and initial dosing of patients in the NSCLC study have now been completed.

-- In July 2008, HGS initiated dosing in the safety lead-in to a randomized Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in patients with advanced hepatocellular cancer, which accounts for 80-90% of all liver cancers.

-- The Company expects to have initial data available in the third quarter of 2008 from a randomized Phase 2 trial of HGS-ETR1 in combination with Velcade (bortezomib) in advanced multiple myeloma. Patients in the multiple myeloma study will continue on treatment until the progression of disease.

These three trials, taken together, will support a decision on whether to advance HGS-ETR1 to Phase 3 development. It also is possible that a sufficiently positive result from any one of the trials could lead to a Phase 3 decision for that specific indication.

About Non-Small Cell Lung Cancer

Non-small cell lung cancer accounts for approximately 75-80% of all lung cancers. It is estimated that more than 170,000 new cases and more than 160,000 deaths occur annually in the United States alone. It is currently the leading cause of cancer death in the U.S. i
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
2. ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
3. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
4. ProteoTechs Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimers Disease
5. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
6. deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
7. New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans
8. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
11. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NEW YORK , Aug. 1, 2014 /PRNewswire/ ... , the largest, independent manufacturer of phosgene and ... , today announced that it has acquired Framochem ... based in Hungary . ... product offerings and creates one of the world,s ...
(Date:8/1/2014)... LAKE FOREST, Ill. , Aug. 1, 2014 ... private equity firm focused exclusively on the healthcare ... Inc. ("Vesta") to The Lubrizol Corporation ("Lubrizol"). Lubrizol, ... company that produces and supplies technologies to customers ... Terms of the transaction were not disclosed. ...
(Date:8/1/2014)... , Aug. 1, 2014 ... of the "Global Medical Biosensors Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Medical biosensors ... help of physicochemical detectors. These biosensors monitor health ... invasive and non-invasive methods. They are cost-effective and ...
Breaking Medicine Technology:VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2
... Jan. 18 ,Exelixis, Inc. (Nasdaq: EXEL ) ... exercise its option to license XL784 for further,development ... meet its primary endpoint in a phase 2 ... in one subgroup were encouraging,Exelixis believes that the ...
... Specialty Pharmacy, one,of the largest privately owned national ... an agreement with Genzyme Corporation to,administer their 2008 ... the world,s largest biotechnology companies dedicated to products,and ... transplant, and oncology., Diplomat will be the ...
Cached Medicine Technology:GSK Does Not Option XL784 for Further Development 2GSK Does Not Option XL784 for Further Development 3Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program 2
(Date:8/1/2014)... August 01, 2014 Stryker hip ... of the 2012 Rejuvenate and ABG II Modular-Neck ... New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... proceeding, the Court has issued a Final ... and all hard copy and electronic materials produced ...
(Date:8/1/2014)... 01, 2014 Summer is here, and with ... during the summer, and they can be a pain for ... to help all their customers get rid of ticks and ... 6,000 eggs in the summer, which is why they are ... tall grass and woodland areas and carry a number of ...
(Date:8/1/2014)... The American Telemedicine Association (ATA) lauds ... Peter Welch (D-VT), for their latest actions to ... of 2014, which improves telemedicine coverage in Medicare. ... healthcare access and affordability using telecommunications technology," said ... cost-saving provisions are critical to improve telehealth coverage ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... others such as Zinc Oxide, Titanium Dioxide, and ... Building & Construction, Food & Beverages, Textiles, and ... ROW) - Global Trends and Forecasts to 2018" ... market drivers, opportunities, and trends in the diverse ...
(Date:8/1/2014)... August 01, 2014 The North America ... security solutions market in North America with analysis and ... from around $3.53 billion in 2014 to $4.77 billion ... to 2019. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:Tis the Season for Tick Prevention 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4
... Taking menstrual cycle into account when booking exam may cut ... (HealthDay News) -- Using a blood test to pinpoint the ... menstrual cycles could reduce the need for repeat scans, U.S. ... MRI scans during the follicular phase (days 3 to14) of ...
... simple blood test corresponding to the follicular phase (days ... optimal scheduling of breast MRI exams in premenopausal women ... repeat scans and non-diagnostic tests patients experience and providing ... to a study published in the December issue of ...
... Virginia Commonwealth University Massey Cancer Center and VCU Institute ... may play a pivotal role in two processes that ... metastasis. Scientists hope the finding could lead to an ... this gene resulting in inhibition of cancer growth. ...
... alcohol dependence problems drink significantly more than do younger adults ... The findings suggest that older problem drinkers may have developed ... than younger abusers to achieve the effects they seek. ... 60 who have alcohol dependence drink more than 40 alcoholic ...
... , NORTHBROOK, Ill., Nov. 20 ... one of the fastest growing cosmetic skin care providers ... injections, Zerona(TM) laser treatments and SmartLipo(TM) body contouring at ... cosmetics industry, new innovations and technologies are constantly being ...
... Mallika Chopra, healthy living expert and founder and CEO ... products in the US, are teaming up to help Americans ... with advice from Chopra, to be posted today on Intent.com. ... the stress or foreboding that typically comes with this time ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:Researchers identify role of gene in tumor development, growth and progression 2Health News:Older problem drinkers use more alcohol than do their younger counterparts 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 3Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Perfect for use in the E.R. Stabilizes collateral ligament strains in seconds and allows hand and finger function. Made from 1/8" AliPlast™ PXE. Can be scissor trimmed....
... Control of thumb motion can be difficult ... for persons with spinal cord injuries and ... to cerebral palsy or other motor or ... the thumb for control and coordination. Soft ...
... ThumWrap Splints offer support without the restriction ... mild pain or strain due to repetitive ... the rigid or the flexible stay to ... Washable and breathable, the ThumWrap Splint is ...
Medicine Products: